Log in to save to my catalogue

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-u...

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-u...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2712850277

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

About this item

Full title

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

Publisher

United States: Elsevier Ltd

Journal title

The Lancet infectious diseases, 2022-12, Vol.22 (12), p.1728-1736

Language

English

Formats

Publication information

Publisher

United States: Elsevier Ltd

More information

Scope and Contents

Contents

Malaria is a leading cause of morbidity and mortality worldwide. We previously reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified goal of 75% or greater efficacy over 12 months in the target population of African children. Here, we report the safety, immunogenicity, and efficacy results at 12 months following...

Alternative Titles

Full title

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2712850277

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2712850277

Other Identifiers

ISSN

1473-3099

E-ISSN

1474-4457

DOI

10.1016/S1473-3099(22)00442-X

How to access this item